<DOC>
	<DOCNO>NCT00676741</DOCNO>
	<brief_summary>The study conduct Europe . The aim observational study evaluate blood glucose control patient use modern insulin : NovoRapid® , NovoMix® 30 Levemir® treatment type 2 diabetes . Full acronym study : COMMIT - CLEAN SWITCH</brief_summary>
	<brief_title>Observational Study Blood Glucose Control Patients With Diabetes Using Modern Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Patients type 2 diabetes Patients treat human soluble insulin , NPH insulin premixed human insulin Patients willing sign inform consent Selection study participant discretion physician Subjects currently treat insulin aspart , insulin detemir biphasic insulin aspart 30 Subjects previously enrol study Subjects hypersensitivity insulin aspart , insulin detemir biphasic insulin aspart 30 excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>